SAB1305546
Anti-β-Actin (ACTB) Antibody
mouse monoclonal, 8H10D10
别名:
ACTB, Actin, cytoplasmic 1, Actin, cytoplasmic 1, N-terminally processed, Beta-actin
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
UNSPSC Code:
12352203
NACRES:
NA.41
Clone:
8H10D10, monoclonal
Species reactivity:
human
Application:
IHC, WB
Citations:
5
产品名称
MONOCLONAL ANTI-BETA-ACTIN antibody produced in mouse, clone 8H10D10, IgG fraction of antiserum, buffered aqueous solution
biological source
mouse
Quality Level
antibody form
IgG fraction of antiserum
antibody product type
primary antibodies
clone
8H10D10, monoclonal
form
buffered aqueous solution
mol wt
41737 Da
species reactivity
human
technique(s)
immunohistochemistry: 1:10-1:50, western blot: 1:2000-1:10000
NCBI accession no.
UniProt accession no.
shipped in
wet ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... ACTB(60)
Application
Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below.
Western Blotting (1 paper)
Western Blotting (1 paper)
Physical form
Supplied in PBS with 0.09% (W/V) sodium azide
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
存储类别
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
常规特殊物品
低风险生物材料
此项目有
Eylem Kulkoyluoglu-Cotul et al.
Cancers, 11(4) (2019-04-17)
A majority of breast cancer specific deaths in women with ERα (+) tumors occur due to metastases that are resistant to endocrine therapy. There is a critical need for novel therapeutic approaches to resensitize recurrent ERα (+) tumors to endocrine
ERα-XPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 Cellular Localization.
Kinga Wrobel et al.
Molecular endocrinology (Baltimore, Md.), 30(10), 1029-1045 (2016-08-18)
Most breast cancer deaths occur in women with recurrent, estrogen receptor (ER)-α(+), metastatic tumors. There is a critical need for therapeutic approaches that include novel, targetable mechanism-based strategies by which ERα (+) tumors can be resensitized to endocrine therapies. The
Eylem Kulkoyluoglu Cotul et al.
Cancers, 12(9) (2020-08-28)
The majority of breast cancer specific deaths in women with estrogen receptor positive (ER+) tumors occur due to metastases that are resistant to therapy. There is a critical need for novel therapeutic approaches to achieve tumor regression and/or maintain therapy
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SAB1305546-400UL | 04061836266646 |